FDA Grants Durvalumab Breakthrough Designation for Bladder Cancer
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational human IgG1 monoclonal antibody durvalumab (MEDI4736) for patients with inoperable or metastatic urothelial bladder cancer that is programmed-cell-death-ligand 1 (PD-L1)-positive and refractory to platinum-based treatment.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational human IgG1 monoclonal antibody durvalumab (MEDI4736) for patients with inoperable or metastatic urothelial bladder cancer that is programmed-cell-death-ligand 1 (PD-L1)-positive and refractory to platinum-based treatment.
“Metastatic bladder cancer is an area of enormous unmet medical need,” said Robert Iannone, MD, Senior Vice President, Head of Immuno-Oncology, Global Medicines Development at AstraZeneca, in a
Durvalumab inhibits PD-L1 binding to PD-1 and CD80, facilitating antitumor immune response. It is undergoing clinical testing as first-line monotherapy and in combination with tremelimumab against bladder cancer in the DANUBE phase III
Breakthrough Therapy Designation hastens drug development for investigational agents that demonstrate substantial clinical improvement over available therapies. The FDA granted this designation to durvalumab after reviewing early phase I clinical trial data, which will be presented at an upcoming medical conference, according to an AstraZeneca press release.
A comprehensive durvalumab registration program is currently underway across multiple tumor types (bladder, head and neck, gastric, pancreatic, liver, blood, and non-small cell lung cancer), stages of disease, and includes various treatment regimens such as durvalumab monotherapy and in combination with other anticancer agents.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025